Copyright Reports & Markets. All rights reserved.

Global Immune Mediated Tumor Killing Assays Service Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Immune Mediated Tumor Killing Assays Service by Type
    • 1.3.1 Overview: Global Immune Mediated Tumor Killing Assays Service Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Immune Mediated Tumor Killing Assays Service Consumption Value Market Share by Type in 2025
    • 1.3.3 Cytotoxic T Cell Assay
    • 1.3.4 Natural Killer (NK) Cell Assay
    • 1.3.5 Other
  • 1.4 Global Immune Mediated Tumor Killing Assays Service Market by Application
    • 1.4.1 Overview: Global Immune Mediated Tumor Killing Assays Service Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Cancer Research
    • 1.4.3 Infectious Disease Research
    • 1.4.4 Immunotherapy Development
  • 1.5 Global Immune Mediated Tumor Killing Assays Service Market Size & Forecast
  • 1.6 Global Immune Mediated Tumor Killing Assays Service Market Size and Forecast by Region
    • 1.6.1 Global Immune Mediated Tumor Killing Assays Service Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Immune Mediated Tumor Killing Assays Service Market Size by Region, (2021-2032)
    • 1.6.3 North America Immune Mediated Tumor Killing Assays Service Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Immune Mediated Tumor Killing Assays Service Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size and Prospect (2021-2032)
    • 1.6.6 South America Immune Mediated Tumor Killing Assays Service Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Immune Mediated Tumor Killing Assays Service Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Agilent
    • 2.1.1 Agilent Details
    • 2.1.2 Agilent Major Business
    • 2.1.3 Agilent Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.1.4 Agilent Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Agilent Recent Developments and Future Plans
  • 2.2 Laboratories
    • 2.2.1 Laboratories Details
    • 2.2.2 Laboratories Major Business
    • 2.2.3 Laboratories Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.2.4 Laboratories Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Laboratories Recent Developments and Future Plans
  • 2.3 Explicyte
    • 2.3.1 Explicyte Details
    • 2.3.2 Explicyte Major Business
    • 2.3.3 Explicyte Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.3.4 Explicyte Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Explicyte Recent Developments and Future Plans
  • 2.4 Reaction Biology
    • 2.4.1 Reaction Biology Details
    • 2.4.2 Reaction Biology Major Business
    • 2.4.3 Reaction Biology Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.4.4 Reaction Biology Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Reaction Biology Recent Developments and Future Plans
  • 2.5 Axion BioSystems
    • 2.5.1 Axion BioSystems Details
    • 2.5.2 Axion BioSystems Major Business
    • 2.5.3 Axion BioSystems Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.5.4 Axion BioSystems Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Axion BioSystems Recent Developments and Future Plans
  • 2.6 Sartorius
    • 2.6.1 Sartorius Details
    • 2.6.2 Sartorius Major Business
    • 2.6.3 Sartorius Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.6.4 Sartorius Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Sartorius Recent Developments and Future Plans
  • 2.7 ICE Bioscience
    • 2.7.1 ICE Bioscience Details
    • 2.7.2 ICE Bioscience Major Business
    • 2.7.3 ICE Bioscience Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.7.4 ICE Bioscience Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 ICE Bioscience Recent Developments and Future Plans
  • 2.8 Shanghai Saily Biotechnology
    • 2.8.1 Shanghai Saily Biotechnology Details
    • 2.8.2 Shanghai Saily Biotechnology Major Business
    • 2.8.3 Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.8.4 Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Shanghai Saily Biotechnology Recent Developments and Future Plans
  • 2.9 ProBio
    • 2.9.1 ProBio Details
    • 2.9.2 ProBio Major Business
    • 2.9.3 ProBio Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.9.4 ProBio Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 ProBio Recent Developments and Future Plans
  • 2.10 Charles River
    • 2.10.1 Charles River Details
    • 2.10.2 Charles River Major Business
    • 2.10.3 Charles River Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.10.4 Charles River Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Charles River Recent Developments and Future Plans
  • 2.11 Imodels
    • 2.11.1 Imodels Details
    • 2.11.2 Imodels Major Business
    • 2.11.3 Imodels Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.11.4 Imodels Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Imodels Recent Developments and Future Plans
  • 2.12 Xeno Diagnostics
    • 2.12.1 Xeno Diagnostics Details
    • 2.12.2 Xeno Diagnostics Major Business
    • 2.12.3 Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.12.4 Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Xeno Diagnostics Recent Developments and Future Plans
  • 2.13 Cyagen
    • 2.13.1 Cyagen Details
    • 2.13.2 Cyagen Major Business
    • 2.13.3 Cyagen Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.13.4 Cyagen Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Cyagen Recent Developments and Future Plans
  • 2.14 MarinBio
    • 2.14.1 MarinBio Details
    • 2.14.2 MarinBio Major Business
    • 2.14.3 MarinBio Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.14.4 MarinBio Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 MarinBio Recent Developments and Future Plans
  • 2.15 Pharmalegacy
    • 2.15.1 Pharmalegacy Details
    • 2.15.2 Pharmalegacy Major Business
    • 2.15.3 Pharmalegacy Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.15.4 Pharmalegacy Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Pharmalegacy Recent Developments and Future Plans
  • 2.16 Celentyx
    • 2.16.1 Celentyx Details
    • 2.16.2 Celentyx Major Business
    • 2.16.3 Celentyx Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.16.4 Celentyx Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Celentyx Recent Developments and Future Plans
  • 2.17 Crown Bioscience
    • 2.17.1 Crown Bioscience Details
    • 2.17.2 Crown Bioscience Major Business
    • 2.17.3 Crown Bioscience Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.17.4 Crown Bioscience Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Crown Bioscience Recent Developments and Future Plans
  • 2.18 Cellomatics Biosciences
    • 2.18.1 Cellomatics Biosciences Details
    • 2.18.2 Cellomatics Biosciences Major Business
    • 2.18.3 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Product and Solutions
    • 2.18.4 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Cellomatics Biosciences Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Immune Mediated Tumor Killing Assays Service Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Immune Mediated Tumor Killing Assays Service by Company Revenue
    • 3.2.2 Top 3 Immune Mediated Tumor Killing Assays Service Players Market Share in 2025
    • 3.2.3 Top 6 Immune Mediated Tumor Killing Assays Service Players Market Share in 2025
  • 3.3 Immune Mediated Tumor Killing Assays Service Market: Overall Company Footprint Analysis
    • 3.3.1 Immune Mediated Tumor Killing Assays Service Market: Region Footprint
    • 3.3.2 Immune Mediated Tumor Killing Assays Service Market: Company Product Type Footprint
    • 3.3.3 Immune Mediated Tumor Killing Assays Service Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Immune Mediated Tumor Killing Assays Service Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Immune Mediated Tumor Killing Assays Service Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Immune Mediated Tumor Killing Assays Service Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Immune Mediated Tumor Killing Assays Service Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Immune Mediated Tumor Killing Assays Service Consumption Value by Type (2021-2032)
  • 6.2 North America Immune Mediated Tumor Killing Assays Service Market Size by Application (2021-2032)
  • 6.3 North America Immune Mediated Tumor Killing Assays Service Market Size by Country
    • 6.3.1 North America Immune Mediated Tumor Killing Assays Service Consumption Value by Country (2021-2032)
    • 6.3.2 United States Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Immune Mediated Tumor Killing Assays Service Consumption Value by Type (2021-2032)
  • 7.2 Europe Immune Mediated Tumor Killing Assays Service Consumption Value by Application (2021-2032)
  • 7.3 Europe Immune Mediated Tumor Killing Assays Service Market Size by Country
    • 7.3.1 Europe Immune Mediated Tumor Killing Assays Service Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 7.3.3 France Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Immune Mediated Tumor Killing Assays Service Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Immune Mediated Tumor Killing Assays Service Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size by Region
    • 8.3.1 Asia-Pacific Immune Mediated Tumor Killing Assays Service Consumption Value by Region (2021-2032)
    • 8.3.2 China Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 8.3.5 India Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Immune Mediated Tumor Killing Assays Service Consumption Value by Type (2021-2032)
  • 9.2 South America Immune Mediated Tumor Killing Assays Service Consumption Value by Application (2021-2032)
  • 9.3 South America Immune Mediated Tumor Killing Assays Service Market Size by Country
    • 9.3.1 South America Immune Mediated Tumor Killing Assays Service Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Immune Mediated Tumor Killing Assays Service Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Immune Mediated Tumor Killing Assays Service Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Immune Mediated Tumor Killing Assays Service Market Size by Country
    • 10.3.1 Middle East & Africa Immune Mediated Tumor Killing Assays Service Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Immune Mediated Tumor Killing Assays Service Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Immune Mediated Tumor Killing Assays Service Market Drivers
  • 11.2 Immune Mediated Tumor Killing Assays Service Market Restraints
  • 11.3 Immune Mediated Tumor Killing Assays Service Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Immune Mediated Tumor Killing Assays Service Industry Chain
  • 12.2 Immune Mediated Tumor Killing Assays Service Upstream Analysis
  • 12.3 Immune Mediated Tumor Killing Assays Service Midstream Analysis
  • 12.4 Immune Mediated Tumor Killing Assays Service Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Immune Mediated Tumor Killing Assays Service market size was valued at US$ 1545 million in 2025 and is forecast to a readjusted size of US$ 2751 million by 2032 with a CAGR of 8.7% during review period.
    Immune cell killing may involve components of the innate and adaptive immune systems, including natural killer (NK) cells, cytotoxic T cells (MHC-dependent), antibodies secreted by B lymphocytes, engineered antibodies such as bispecific antibodies and bispecific T-cell engagers (BiTEs), and genetically engineered T cells directed against specific tumor antigens (e.g., CAR-T, MHC-independent).
    This report is a detailed and comprehensive analysis for global Immune Mediated Tumor Killing Assays Service market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Immune Mediated Tumor Killing Assays Service market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Immune Mediated Tumor Killing Assays Service market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Immune Mediated Tumor Killing Assays Service market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Immune Mediated Tumor Killing Assays Service market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Immune Mediated Tumor Killing Assays Service
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Immune Mediated Tumor Killing Assays Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Agilent, Laboratories, Explicyte, Reaction Biology, Axion BioSystems, Sartorius, ICE Bioscience, Shanghai Saily Biotechnology, ProBio, Charles River, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Immune Mediated Tumor Killing Assays Service market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Cytotoxic T Cell Assay
    Natural Killer (NK) Cell Assay
    Other
    Market segment by Application
    Cancer Research
    Infectious Disease Research
    Immunotherapy Development
    Market segment by players, this report covers
    Agilent
    Laboratories
    Explicyte
    Reaction Biology
    Axion BioSystems
    Sartorius
    ICE Bioscience
    Shanghai Saily Biotechnology
    ProBio
    Charles River
    Imodels
    Xeno Diagnostics
    Cyagen
    MarinBio
    Pharmalegacy
    Celentyx
    Crown Bioscience
    Cellomatics Biosciences
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Immune Mediated Tumor Killing Assays Service product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Immune Mediated Tumor Killing Assays Service, with revenue, gross margin, and global market share of Immune Mediated Tumor Killing Assays Service from 2021 to 2026.
    Chapter 3, the Immune Mediated Tumor Killing Assays Service competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Immune Mediated Tumor Killing Assays Service market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Immune Mediated Tumor Killing Assays Service.
    Chapter 13, to describe Immune Mediated Tumor Killing Assays Service research findings and conclusion.

    Buy now